NCT05283044

Implementing Precision Medicine in cOmmunity HospiTALs

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 10,000 (estimated)
• Sponsor: Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting

Detailed description

Patients will be selected to present a metastatic cancer (de novo or relapse after primary tumor treatment) eligible for a first line treatment (chemotherapy, immunotherapy, endocrine therapy or targeted therapy). All tumor subtype could be enrolled in the study; metastatic prostate cancer must be resistant to castration. Triple negative breast cancer and Hormone receptor positive, Her2-negative metastatic breast cancer resistant to endocrine therapy are eligible to the study. A plasma sample will be collected at baseline and will be tested for a large panel of gene and MSI status using Next Generation Sequencing (NGS) (cf table). Results will be discussed within a Molecular Tumor Board (MTB) with all declared centers.

Conditions

• Metastatic Cancer

Interventions

Type	Name	Description
BIOLOGICAL	biopsy liquid	Patient performs a blood test at treatment baseline

Timeline

• Start date: 2022-06-29
• Primary completion: 2028-11-15
• Completion: 2030-04-15
• First posted: 2022-03-16
• Last updated: 2025-06-25

Locations

21 sites across 3 countries: France, French Polynesia, New Caledonia